-platin
A platinum cancer drug that cross-links DNA.
- Drugs ending in -platin: 12
- Approved somewhere: 3
- With a US drug page: 3
- Stem
- -platin
- Class
- Platinum cancer drugs, like cisplatin
- Most common targets
- DNA (5)
Approved and clinical-stage drugs in ChEMBL whose names ending in -platin, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Carboplatin | Approved | DNA | DNA inhibitor |
| Cisplatin | Approved | DNA | DNA inhibitor |
| Oxaliplatin | Approved | DNA | DNA inhibitor |
| Demplatin pegraglumer | Phase 3 | — | — |
| Lobaplatin | Phase 3 | — | — |
| Nedaplatin | Phase 3 | — | — |
| Picoplatin | Phase 3 | DNA | DNA cross-linking agent |
| Satraplatin | Phase 3 | — | — |
| Transplatin | Phase 3 | — | — |
| Aroplatin | Phase 2 | — | — |
| Triplatin tetranitrate | Phase 2 | DNA | DNA disrupting agent |
| Imifoplatin | Phase 1 | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO